Is Eplerenone a Diuretic?
Yes, eplerenone is classified as a potassium-sparing diuretic, specifically a selective mineralocorticoid receptor (MR) antagonist. 1
Mechanism and Classification
Eplerenone functions as a potassium-sparing diuretic through selective blockade of mineralocorticoid receptors in the distal nephron, where it interferes with sodium reabsorption and potassium excretion 2. The FDA label explicitly contraindicates its use with other potassium-sparing diuretics (amiloride, spironolactone, triamterene) in hypertensive patients, confirming its classification within this drug class 1.
Key Distinguishing Features
Unlike traditional diuretics, eplerenone's primary therapeutic value extends beyond simple volume management:
- Selective MR antagonism: Eplerenone has 50-60% of spironolactone's MR antagonist potency but lacks antiandrogen and progesterone agonist effects 3, 4
- Reduced endocrine side effects: The selectivity translates to significantly lower rates of gynecomastia (infrequent vs. 10% with spironolactone) and menstrual irregularities 5, 6
- Twice-daily dosing required: Due to its shorter half-life compared to spironolactone 3, 4
Clinical Context and Comparison
While technically a diuretic, eplerenone is not primarily used for volume management like thiazides or loop diuretics. The Endocrine Society guidelines explicitly distinguish it from epithelial sodium channel blockers (amiloride, triamterene), noting that amiloride is described as "being a potassium-sparing diuretic" when discussing alternatives to spironolactone 3. This phrasing suggests eplerenone occupies a somewhat distinct therapeutic niche despite sharing the same drug class.
Evidence-Based Indications
Heart failure: Eplerenone reduces mortality and hospitalizations in post-MI patients with LVEF ≤40% and in symptomatic HFrEF (NYHA class II-IV) 7, 5, 8
Hypertension: Approved for essential hypertension, though guidelines favor spironolactone for resistant hypertension due to stronger evidence 9, 10. Eplerenone may require higher doses (up to 100 mg daily) for adequate BP control 4
Primary aldosteronism: Serves as an alternative when spironolactone side effects prove intolerable, though it has 50% less MR antagonist potency 4
Critical Safety Considerations
The potassium-sparing effect creates significant hyperkalemia risk:
- Contraindicated if serum potassium >5.5 mEq/L or creatinine clearance ≤30 mL/min 1
- Mandatory monitoring: Check potassium within first week, at one month, then periodically 1
- Dose adjustments: Halve dose if K+ 5.5-5.9 mEq/L; discontinue if ≥6.0 mEq/L 5, 6, 7
- Drug interactions: Reduce dose by 50% with moderate CYP3A inhibitors; avoid strong CYP3A inhibitors entirely 1
Common Pitfall
The 2025 AHA/ACC guidelines note that 4-40% of patients cannot tolerate spironolactone due to hyperkalemia or antiandrogenic effects 9. However, eplerenone trials at standard doses (25-100 mg daily) have not consistently demonstrated BP reduction comparable to spironolactone in resistant hypertension, potentially requiring higher dosages 9. This creates a clinical dilemma where the better-tolerated agent may be less effective.
Bottom Line
Eplerenone is definitively a potassium-sparing diuretic by mechanism and FDA classification, but its clinical role centers on MR antagonism for cardiovascular protection rather than diuresis per se. It represents a selective, better-tolerated alternative to spironolactone when endocrine side effects are problematic, though with reduced potency requiring careful dose titration and vigilant potassium monitoring.